Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

HCV RNA Levels Following Virologic Failure with Direct-Acting Antivirals: Implications for Lower Sensitivity Diagnostic Assays.

Harrington PR, Komatsu TE, Sun H, Naeger LK.

Clin Infect Dis. 2019 May 10. pii: ciz385. doi: 10.1093/cid/ciz385. [Epub ahead of print]

PMID:
31075159
2.

HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens.

Boyd SD, Harrington P, Komatsu TE, Naeger LK, Chan-Tack K, Murray J, Birnkrant D, Struble K.

J Viral Hepat. 2018 Aug;25(8):969-975. doi: 10.1111/jvh.12896. Epub 2018 May 8.

PMID:
29577495
3.

Impact of hepatitis C virus polymorphisms on direct-acting antiviral treatment efficacy: Regulatory analyses and perspectives.

Harrington PR, Komatsu TE, Deming DJ, Donaldson EF, O'Rear JJ, Naeger LK.

Hepatology. 2018 Jun;67(6):2430-2448. doi: 10.1002/hep.29693.

PMID:
29194682
4.

Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.

Struble K, Chan-Tack K, Qi K, Naeger LK, Birnkrant D.

Hepatology. 2018 Feb;67(2):482-491. doi: 10.1002/hep.29601. Epub 2018 Jan 1.

PMID:
29059462
5.

Regulatory Analysis of Effects of Hepatitis C Virus NS5A Polymorphisms on Efficacy of Elbasvir and Grazoprevir.

Komatsu TE, Boyd S, Sherwat A, Tracy L, Naeger LK, O'Rear JJ, Harrington PR.

Gastroenterology. 2017 Feb;152(3):586-597. doi: 10.1053/j.gastro.2016.10.017. Epub 2016 Oct 20.

PMID:
27773808
6.

Effect of dolutegravir functional monotherapy on HIV-1 virological response in integrase strand transfer inhibitor resistant patients.

Naeger LK, Harrington P, Komatsu T, Deming D.

Antivir Ther. 2016;21(6):481-488. doi: 10.3851/IMP3033. Epub 2016 Feb 11.

PMID:
26866979
7.

Regulatory evaluation of antiviral drug resistance in the era of next-generation sequencing.

Donaldson EF, Deming DJ, O'Rear JJ, Naeger LK.

Biomark Med. 2015;9(11):1047-51. doi: 10.2217/bmm.15.63. Epub 2015 Oct 28. No abstract available.

8.

Hepatitis C Virus RNA Levels During Interferon-Free Combination Direct-Acting Antiviral Treatment in Registrational Trials.

Harrington PR, Deming DJ, Komatsu TE, Naeger LK.

Clin Infect Dis. 2015 Aug 15;61(4):666-7. doi: 10.1093/cid/civ402. Epub 2015 May 22. No abstract available.

PMID:
26002846
9.

FDA perspective on sofosbuvir therapy for patients with chronic hepatitis C virus genotype 1 infection who did not respond to treatment with pegylated interferon and ribavirin.

Mishra P, Florian J, Qi K, Zeng W, Naeger LK, Donaldson E, Connelly S, O'Rear J, Price D, Murray J, Birnkrant D.

Gastroenterology. 2014 Dec;147(6):1196-200. doi: 10.1053/j.gastro.2014.10.027. Epub 2014 Oct 27. No abstract available.

PMID:
25449024
10.

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.

Donaldson EF, Harrington PR, O'Rear JJ, Naeger LK.

Hepatology. 2015 Jan;61(1):56-65. doi: 10.1002/hep.27375. Epub 2014 Nov 20.

PMID:
25123381
11.

Resistance of human cytomegalovirus to ganciclovir/valganciclovir: a comprehensive review of putative resistance pathways.

Komatsu TE, Pikis A, Naeger LK, Harrington PR.

Antiviral Res. 2014 Jan;101:12-25. doi: 10.1016/j.antiviral.2013.10.011. Epub 2013 Oct 31. Review.

PMID:
24184129
12.

Reply: To PMID 22095516.

Harrington PR, Naeger LK, Zeng W.

Hepatology. 2013 Feb;57(2):856. doi: 10.1002/hep.25948. No abstract available.

PMID:
22806687
13.

Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment.

Harrington PR, Zeng W, Naeger LK.

Hepatology. 2012 Apr;55(4):1048-57. doi: 10.1002/hep.24791. Epub 2012 Mar 1.

PMID:
22095516
14.

Running a tightrope: regulatory challenges in the development of antiretrovirals.

Naeger LK, Struble KA, Murray JS, Birnkrant DB.

Antiviral Res. 2010 Jan;85(1):232-40. doi: 10.1016/j.antiviral.2009.07.016. Epub 2009 Aug 7. Review.

PMID:
19665489
15.
17.

Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir.

Tuske S, Sarafianos SG, Clark AD Jr, Ding J, Naeger LK, White KL, Miller MD, Gibbs CS, Boyer PL, Clark P, Wang G, Gaffney BL, Jones RA, Jerina DM, Hughes SH, Arnold E.

Nat Struct Mol Biol. 2004 May;11(5):469-74. Epub 2004 Apr 25.

PMID:
15107837
18.
19.

Distinct requirements for the naturally occurring splice forms Stat4alpha and Stat4beta in IL-12 responses.

Hoey T, Zhang S, Schmidt N, Yu Q, Ramchandani S, Xu X, Naeger LK, Sun YL, Kaplan MH.

EMBO J. 2003 Aug 15;22(16):4237-48.

20.
21.

Th1 cells regulate hematopoietic progenitor cell homeostasis by production of oncostatin M.

Broxmeyer HE, Bruns HA, Zhang S, Cooper S, Hangoc G, McKenzie AN, Dent AL, Schindler U, Naeger LK, Hoey T, Kaplan MH.

Immunity. 2002 Jun;16(6):815-25.

22.
23.

Mechanisms of HIV-1 nucleoside reverse transcriptase inhibitor resistance: is it all figured out?

Naeger LK, Miller MD.

Curr Opin Investig Drugs. 2001 Mar;2(3):335-9. Review.

PMID:
11575701
24.

Tenofovir (PMPA) is less susceptible to pyrophosphorolysis and nucleotide-dependent chain-terminator removal than zidovudine or stavudine.

Naeger LK, Margot NA, Miller MD.

Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):635-9.

PMID:
11563081
26.

E2F-Rb complexes assemble and inhibit cdc25A transcription in cervical carcinoma cells following repression of human papillomavirus oncogene expression.

Wu L, Goodwin EC, Naeger LK, Vigo E, Galaktionov K, Helin K, DiMaio D.

Mol Cell Biol. 2000 Oct;20(19):7059-67.

28.

Identification of a STAT4 binding site in the interleukin-12 receptor required for signaling.

Naeger LK, McKinney J, Salvekar A, Hoey T.

J Biol Chem. 1999 Jan 22;274(4):1875-8.

31.
32.

Supplemental Content

Loading ...
Support Center